Endometrial Ablation Devices Market Report 2025

The endometrial ablation devices market size has grown strongly in recent years. It will grow from $3.67 billion in 2024 to $3.9 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to changing attitudes towards women's health, rising incidence of abnormal uterine bleeding, demand for alternatives to hysterectomy, and shift towards outpatient procedures.

The endometrial ablation devices market size is expected to see strong growth in the next few years. It will grow to $5.13 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing awareness and education, emphasis on fertility preservation, personalized medicine approach, regulatory support and guidelines, and focus on office-based procedures. Major trends in the forecast period include the integration of telemedicine and remote consultations, standardization of protocols, the shift towards non-hormonal treatment, integration of patient-centric care, and development of safer procedures.

The growth of the endometrial ablation devices market is anticipated to be fueled by the increasing prevalence of gynecological disorders. Gynecological disorders encompass various medical conditions affecting the female reproductive system, including menstrual disorders, endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, pelvic inflammatory disease (PID), and ovarian cysts. Endometrial ablation devices play a crucial role in treating these disorders by destroying the endometrial lining, providing relief from heavy menstrual bleeding, and addressing conditions such as adenomyosis and endometrial hyperplasia. As of June 2023, the World Health Organization reports that PCOS affects 8-13% of reproductive-aged women, with up to 70% of affected women globally going misidentified. This increasing prevalence underscores the driving force behind the growth of the endometrial ablation devices market.

The growth in healthcare spending is anticipated to drive the expansion of the endometrial ablation devices market in the coming years. Healthcare expenditure refers to the total financial resources allocated for healthcare services, products, and infrastructure within a specific country, region, or organization. Targeted and efficient healthcare spending enhances the connectivity, safety, and overall effectiveness of endometrial ablation procedures, leading to improved outcomes for women with gynecological conditions. For instance, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to the previous year. Therefore, the rise in healthcare spending is fueling the growth of the endometrial ablation devices market.

Leading companies in the endometrial ablation devices market are concentrating on securing regulatory approvals to introduce innovative products and expand their market presence. Regulatory approvals involve formal authorization granted by government agencies or regulatory bodies, ensuring that a medical device, drug, or treatment meets the required safety and efficacy standards before it can be sold or utilized in a specific region. For example, in February 2023, Hologic Inc., a US-based health technology firm, received regulatory approval for its NovaSure V5 Global Endometrial Ablation Device in both Canada and Europe. This device, designed for the treatment of abnormal uterine bleeding through a minimally invasive procedure, includes advanced technologies such as SmartDepth for precise ablation and SureClear for effective suction during the procedure. It allows for personalized treatment for individual patients, with clinical outcomes showing a 97% satisfaction rate, 75% of patients experiencing amenorrhea after five years, and 86% avoiding hysterectomy after ten years.

Key players in the endometrial ablation devices market are also working on developing advanced solutions like field ablation systems to improve efficacy and patient comfort. A field ablation system is a medical device used to treat abnormal tissue, particularly in the heart, by applying energy (such as radiofrequency, laser, or cryotherapy) to a specific area. For instance, in January 2024, Abbott Laboratories, a US-based medical device company, launched its Volt Pulsed Field Ablation (PFA) System, marking the beginning of human trials aimed at treating atrial fibrillation (AFib). This cutting-edge technology uses pulsed field energy to selectively target heart muscle cells, minimizing collateral damage to surrounding tissues compared to traditional thermal ablation techniques. The system features a balloon-in-basket catheter design for greater precision and stability, and integrates with the EnSite X cardiac mapping platform to improve procedural accuracy. Initial trials are being conducted in Australia, with plans for global expansion, positioning Abbott as a leader in AFib treatment as demand for advanced therapies grows.

In August 2022, Medtronic, an Ireland-based medical device company, acquired Affera for $925 million. This acquisition allows Medtronic to enhance its cardiac ablation portfolio and advance electrophysiology technology, improving treatment options for patients with heart rhythm disorders. This strategic move strengthens Medtronic's ability to support physicians and increases its market presence in the growing cardiac care sector. Affera, a US-based medical technology company, focuses on developing cardiac ablation devices for treating arrhythmias.

Major companies operating in the endometrial ablation devices market include Johnson and Johnson Private Limited, Medtronic Plc., Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Smith And Nephew plc., Hologic Inc., C R.Bard Inc., Cooper Companies Inc., Cook Medical, Karl Storz GmbH And Co. KG, Biotronik SE And Co. KG, B. Braun Medical Inc., Richard Wolf GmbH, Aesculap Inc., AngioDynamics, Gyrus ACMI Inc., Minerva Surgical Inc., Lina Medical ApS, Biolitec AG, AEGEA Medical Inc., Albyn Medical,Channel Medsystems Inc., CathRX Ltd, Ecleris Srl., Idoman Teoranta, Surkon Medical Co. Ltd, Omnitech Systems Inc., Veldana Medical SA.

North America was the largest region in the endometrial ablation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endometrial ablation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endometrial ablation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Endometrial ablation devices encompass a range of medical tools specifically engineered for conducting procedures involving the removal or destruction of the uterine lining. These devices are instrumental in addressing gynecological conditions associated with irregular uterine bleeding.

The various categories of endometrial ablation devices exist, including hysteroscopy devices, thermal balloon ablators, radiofrequency endometrial ablation devices, hydrothermal ablators, electrical ablators, and others. Hysteroscopy devices encompass a suite of medical tools employed in the diagnostic and therapeutic practice of hysteroscopy. These technologies, comprising radiofrequency ablation, cryoablation, hydrothermal ablation, thermal balloon procedures, and hysteroscopic ablation, cater to diverse end-users such as ambulatory surgery centers, clinics, and hospitals.

The endometrial ablation devices market research report is one of a series of new reports that provides endometrial ablation devices market statistics, including endometrial ablation devices industry global market size, regional shares, competitors with an endometrial ablation devices market share, detailed endometrial ablation devices market segments, market trends and opportunities, and any further data you may need to thrive in the endometrial ablation devices industry. This endometrial ablation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometrial ablation devices market consists of sales of radiofrequency ablation devices, cryoablation devices, hydrothermal devices, and microwave ablation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.